Loading...
•
Sep 30, 2021
Mersana Q3 2021 Earnings Report
Mersana Therapeutics reported financial results for the third quarter ended September 30, 2021 and provided a business update.
Key Takeaways
Mersana Therapeutics reported cash and cash equivalents of $191.7 million as of September 30, 2021. Net cash used in operating activities in the third quarter of 2021 was $36.1 million. The Company expects that its available funds will be sufficient to support its operating plan commitments into the first half of 2023.
Upifitamab Rilsodotin (UpRi), first-in-class Dolaflexin ADC targeting NaPi2b.
XMT-1592, first Dolasynthen ADC targeting NaPi2b.
XMT-1660, first-in-class Dolasynthen ADC targeting B7-H4.
XMT-2056, first-in-class HER2-targeted Immunosynthen STING-agonist ADC
Forward Guidance
Mersana Therapeutics expects UPLIFT to be fully enrolled, UP-NEXT to be initiated and enrolling, UPGRADE to be charting the path in combinations and to have multiple assets in the clinic addressing a diverse set of targets.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...